Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dyne Therapeutics Inc
(NQ:
DYN
)
32.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Dyne Therapeutics Inc
< Previous
1
2
3
4
Next >
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
September 03, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
September 03, 2024
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...
Via
Benzinga
Recap: Dyne Therapeutics Q4 Earnings
March 05, 2024
Via
Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
September 03, 2024
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.
Via
Investor's Business Daily
Nasdaq Dips Over 2%; US Construction Spending Falls In July
September 03, 2024
Via
Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
September 03, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 03, 2024
Via
Benzinga
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
August 21, 2024
Find out the significance of the
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
August 13, 2024
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
August 12, 2024
DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
July 10, 2024
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United...
Via
Talk Markets
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
June 12, 2024
Via
Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
June 12, 2024
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Why Is Dyne Therapeutics Stock Soaring On Monday?
May 20, 2024
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...
Via
Benzinga
Tech Surge Boosts Nasdaq To Record Highs
May 20, 2024
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.
Via
Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
May 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 20, 2024
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!
Via
InvestorPlace
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
May 02, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
March 14, 2024
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven...
Via
Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
March 08, 2024
Via
Benzinga
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
March 06, 2024
Via
Benzinga
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
March 05, 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.